Juxtarenal Aortic Aneurysm, Suprarenal Aortic Aneurysm, Thoracoabdominal Aortic Aneurysm
Conditions
Keywords
Complex Aortic Aneurysm, Complex Abdominal Aortic Aneurysm, Aneurysm
Brief summary
The primary objective of this study is to assess the use of a physician-modified Cook Alpha Thoracic Endovascular Graft in the repair of complex aortic aneurysms and thoracoabdominal aortic aneurysms and aneurysms secondary to aortic dissections in high-risk patients having appropriate anatomy. The primary intent of the study is to assess the safety and preliminary effectiveness of the device. Additionally, the study will assess renal function, radiation exposure, and quality of life.
Detailed description
This study is a prospective, single-center, non-randomized, single-arm study. Each enrolled subject will undergo periodic follow-up evaluations involving physical exams, computed tomography angiography (CTA) of chest, abdomen and pelvis, abdominal duplex ultrasound, creatinine measurement, quality of life questionnaire at specific, protocol-defined intervals for a period of five years following the physician-modified Cook Zenith® Alpha Endovascular Graft implant.
Interventions
DEVICEPhysician-Modified Cook Zenith Alpha Thoracic Endovascular Graft
Cook Zenith® Alpha Thoracic Endovascular Graft will be modified to allow for the maintenance of blood flow into the visceral and renal branch vessels.
Sponsors
Medstar Health Research Institute
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age ≥ 18 years old 2. Life expectancy \> 2 year(s) 3. Patient is considered to be at high risk of morbidity and mortality with open surgical repair 4. A patient may be entered into the study if the patient has at least one of the following: * Juxtarenal, suprarenal or a thoracoabdominal aortic aneurysm with a diameter ≥ 5.5 cm or 2 times the normal aortic diameter * Aneurysm with a history of growth ≥ 0.5 cm per year * Saccular aneurysms deemed at significant risk for rupture based upon physician interpretation * Symptomatic juxtarenal, suprarenal or a thoracoabdominal aortic aneurysm * Thoracoabdominal aortic aneurysms secondary to aortic dissection meeting above criteria 5. Patient is considered to be at high risk of morbidity and mortality with open surgical repair 6. Iliac or femoral access vessel morphology that is compatible with vascular access techniques, devices or accessories, with or without use of a surgical conduit 7. Nonaneurysmal aortic segment proximal to the aneurysm (neck) with a: * Minimum neck length of 20mm * Diameter in the range of 21-38mm * Angle less than 60° relative to the axis of the aneurysm * Angle less than 60° relative to the axis of the suprarenal aorta 8. Minimum branch vessel diameter greater than 5 mm 9. Iliac artery distal fixation site greater than 10mm in length and diameter in the range of 8-21mm.
Exclusion criteria
1. Under the age of 18 years 2. Can be treated in accordance with the instructions for use with a legally marketed endovascular prosthesis 3. Is eligible for enrollment in a manufacturer-sponsored IDE at the investigational site 4. Willing to participate in a sponsor-investigator IDE with access to a non-physician modified endovascular prostheses at the investigational site 5. Willing to travel to an investigational site with access to a non-physician modified endovascular prosthesis 6. Unwilling or unable to comply with the follow-up schedule 7. Inability or refusal to give informed consent by patient or legal representative 8. Patient is pregnant or breastfeeding 9. Life expectancy \< 2-years despite successful aneurysm exclusion 10. Free rupture with hemodynamic instability 11. Ongoing infection 12. Diagnosis of, or suspected connective tissue disease 13. Known sensitivities or allergies to the materials of construction of the devices 14. Known hypersensitivity or contraindication to anticoagulation or contrast media that cannot be adequately medically managed 15. Uncorrectable coagulopathy 16. Body habitus that would inhibit x-ray visualization of the aorta or exceeds the safe capacity of the equipment 17. Patient has had a major surgical or interventional procedure unrelated to the treatment of the aneurysm planned ≤ 30 days of the endovascular repair 18. Unstable angina (defined as angina with a progressive increase in symptoms, new onset at rest or nocturnal angina) 19. Systemic or local infection that may increase the risk of endovascular graft infection 20. Leaking or free rupture of aneurysm associated with hemodynamic instability. 21. Baseline creatinine greater than 3.0 mg/dL 22. Known history of, or suspected connective tissue disorders (e.g., Marfan Syndrome, Ehler's Danlos Syndrome) Anatomical
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Freedom from Major Adverse Events (MAE) at 30 days | 30 days | Major Adverse Events include: Death, Bowel Ischemia, myocardial infarction, paraplegia/paraparesis, renal failure, respiratory failure, and stroke |
| Proportion of study subjects with treatment success at 1 year | 1 year | Treatment success is defined as a composite of technical success and freedom from the following: * Aneurysm enlargement \[i.e., \>5mm) as compared to a preoperative CT measure using orthogonal (i.e, perpendicular to the centerline) measurements\] * Aneurysm rupture * Aneurysm-related mortality * Conversion to open repair * Secondary intervention for migration, Type I and III endoleaks, device integrity failure (e.g., fracture), and patency-related events (i.e., device component stenosis or occlusion and embolic events) |
| Technical success | 1 year | Technical success is defined as: * Successful delivery (i.e., ability to deliver the implant to the intended implantation site, without the need for unanticipated corrective intervention related to delivery) and deployment of the device at the intended location, * Patency of all endovascular graft and branch stent components * Absence of device deformations requiring unplanned placement of an additional device * Absence of inadvertent covering of aortic branch vessels * Successful withdrawal (i.e., successful withdrawal of the delivery system, without need for unanticipated corrective intervention related to withdrawal) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Quality of Life measures | 30 days, 6 months; 1, 2, 3, 4 and 5 years | Questionnaire using SF - 36™ Health Survey |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORJavairiah Fatima, MD
Medstar Health Research Institute
Outcome results
None listed